C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.

Latent autoimmune diabetes in adults (LADA) is a slowly progressing form of immune-mediated diabetes often misdiagnosed as type 2 diabetes because of its typical clinical presentation, i.e., an adult without weight loss or ketoacidosis not initially requiring insulin (1). Prior to insulin dependence, pharmacological options for reducing hyperglycemia comprise the oral glucose-lowering drugs used in type2diabetes; however, nonehas been established as the drug of choice in LADA because of the scarcity of evidence for or against the various agents (2).